Autolus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	75.39	10.12	1.7	6.36	2.33
Revenue Growth (YoY)	644.94%	496.00%	-73.30%	172.96%	35.86%
Cost of Revenue	207.38	141.02	122.31	117.35	110.84
Gross Profit	-132	-130.9	-120.62	-110.99	-108.51
Selling, General & Admin	138.2	110.11	54.91	31.9	31.87
Operating Expenses	138.2	110.11	54.91	31.9	31.87
Operating Income	-270.2	-241.01	-175.53	-142.89	-140.37
Interest Expense	-42.37	-39.94	-45.07	-8.91	-1.11
Interest & Investment Income	18.98	32.36	13.51	1.71	0.26
Currency Exchange Gain (Loss)	2.16	-0.99	2.64	1.8	-2.3
Other Non Operating Income (Expenses)	6.21	30.86	0.22	0.34	0.16
EBT Excluding Unusual Items	-285.21	-218.72	-204.23	-147.95	-143.36
Gain (Loss) on Sale of Assets	-	-	-3.79	-0.52	-0.68
Asset Writedown	-0.35	-0.41	-0.38	-	-
Other Unusual Items	-	-	-	-0.1	2
Pretax Income	-285.56	-219.13	-208.4	-148.57	-142.04
Income Tax Expense	1.97	1.53	-0.02	0.27	0.06
Net Income	-287.53	-220.66	-208.38	-148.84	-142.1
Net Income to Common	-287.53	-220.66	-208.38	-148.84	-142.1
Shares Outstanding (Basic)	266	255	174	95	72
Shares Outstanding (Diluted)	266	255	174	95	72
Shares Change (YoY)	4.30%	46.69%	83.11%	31.78%	39.81%
EPS (Basic)	-1.08	-0.86	-1.20	-1.57	-1.97
EPS (Diluted)	-1.08	-0.86	-1.20	-1.57	-1.97
Free Cash Flow	-302.61	-228.35	-156.57	-123.15	-126.72
Free Cash Flow Per Share	-1.14	-0.90	-0.90	-1.30	-1.76
Gross Margin	-175.09%	-	-	-	-
Operating Margin	-358.41%	-2381.54%	-10337.34%	-2246.74%	-6024.64%
Profit Margin	-381.40%	-2180.45%	-12272.26%	-2340.24%	-6098.54%
Free Cash Flow Margin	-401.41%	-2256.38%	-9221.02%	-1936.31%	-5438.54%
EBITDA	-260.38	-233.3	-168.96	-135.54	-132.01
D&A For EBITDA	9.81	7.72	6.57	7.36	8.37
EBIT	-270.2	-241.01	-175.53	-142.89	-140.37
Revenue as Reported	75.39	10.12	1.7	-	-

Updated Mar 27, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q